Owkin is an AI biotechnology company on a mission to find the right treatment for every patient. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools.
We use federated data access to unlock valuable insights from patient data while protecting patient privacy and securing proprietary data. We integrate the best of human and artificial intelligence to answer the research questions challenging biopharma and academic researchers.
Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).